ReNeuron Announces Successful Completion Of Cell Banking With ReN001 Stem Cell Therapy For Stroke

ReNeuron Group plc (LSE: RENE.L) today announces that it has successfully completed the scale-up and cell banking of its lead ReN001 stem cell product for stroke. Master and Working cell banks have been manufactured to full Good Manufacturing Practice (GMP) standard, having been fully tested for purity, sterility and stability. The banking and testing process took place at a contract manufacturer in the UK.

Back to news